Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-03-26
2010-02-02
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024100, C536S024500, C435S006120, C435S375000, C435S377000
Reexamination Certificate
active
07655634
ABSTRACT:
Novel methods of regulating cellular apoptosis by affecting the interaction of hepatitis B X-interacting protein (HBXIP) with Survivin are described. More specifically, these novel methods of enhancing apoptosis of neoplastic cells comprises inhibiting interaction of hepatitis B X-interacting protein (HBXIP) with Survivin using siRNA or antisense compounds.
REFERENCES:
patent: 6838283 (2005-01-01), Bennett et al.
patent: 2003/0206887 (2003-11-01), Morrissey et al.
patent: 2004/0072170 (2004-04-01), Bunk et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
Ambrosini, G. et al. “A novel anti-apoptosis gene,survivin, expressed in cancer and lymphoma.”Nature Med3:917-921 (1997).
Banks, D.P. et al. “Survivin does not inhibit caspase-3 activity.”Blood96:4002-4003 (2000).
Bratton, S.B. et al. “Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. ”EMBO J20:998-1009 (2001).
Cryns, V. et al. “Proteases to die for.”Genes Dev12:1551-1570 (1998).
Deveraux, Q.L. et al. “IAP family proteins: Suppressors of apoptosis.”Genes Dev13:239-252 (1999).
Deveraux, Q.L. et al. “X-linked IAP is a direct inhibitor of cell death proteases.”Nature388:300-304 (1997).
Gottlob, K. et al. “The Hepatitis B virus HBx protein inhibits caspase 3 activity.”J Biol Chem273:33347-33353 (1998).
Grossman, D. et al. “Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53.”J Clin.Invest108:991-999 (2001).
Kim, C.M. et al. “HBx gene of hepatitis B virus induces liver cancer in transgenic mice. ”Nature351:317-320 (1991).
Li, F. et al. “Control of apoptosis and mitotic spindle checkpoint by survivin.”Nature396:580-584 (1998).
Li, P. et al. “Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade.”Cell91:479-489 (1997).
Lok, A.S. “Hepatitis B infection: Pathogenesis and management.”J Hepatol32:89-97 (2000).
Marusawa, H. et al. “HBXIP functions as a cofactor of survivin in apoptosis suppression”The EMBO J.22:2729-2740 (2003).
Marusawa, H. et al. “Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen.”Hepatology31:488-495 (2000).
Matsuzawa, S. et al. “Siah-1, SIP, and Ebi collaborate in a novel pathway for -catenin degradation linked to p53 responses.”Mol Cell7:915-926 (2001).
Melegari, M. et al. “Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication.”J Virol72:1737-1743 (1998).
Murakami S. “Hepatitis B virus X protein: A multifunctional viral regulator.”J Gastroenterol36:651-660 (2001).
O'Connor, D.S. et al. “Regulation of apoptosis at cell division by p34cdc2phosphorylation of survivin.”PNAS USA97:13103-13107 (2000).
Reed, J.C. et al. “BIRinging chromosomes through cell division—and survivin the experience.”Cell102: 545-548 (2000).
Reed, J.C. “The survivin saga goes in vivo.”J Clin Invest108:965-969 (2001).
Riedl, S.J. et al. “Structural basis for the inhibition of caspase-3 by XIAP.”Cell104:791-800 (2001).
Salvesen, G.S. “Caspases: opening the boxes and interpreting the arrows.”Cell Death Differ9:3-5 (2002).
Shin, S. et al. “An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7.”Biochem40: 1117-1123 (2001).
Stennicke, H.R. et al. “Caspase-9 can be activated without proteolytic processing.”J Biol Chem274:8359-8362 (1999).
Sun, C. et al. “NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP.”Nature401:818-822 (1999).
Tamm, I. et al. “IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.”Cancer Res58:5315-5320 (1998).
Yagihashi, A. et al. “Detection of anti-survivin antibody in gastrointestinal cancer patients” Clin. Chem. 47 :1729-1731 (2001).
Velculescu, V.E. et al. “Analysis of human transcriptomes.”Nature Gen23:387-388 (1999).
Verdecia, M.A. et al. “Structure of the Human anti-apoptotic protein survivin reveals a dimeric arrangement.”Nature Struct Biol7:602-608 (2000).
Yang, J. et al. “Prevention of apoptosis by Bc1-2: release of cytochrome c from mitochondria blocked.”Science275: 1129-1132 (1997).
Zhou, Q. et al. “Target protease specificity of the viral serpin CrmA: analysis of five caspases.”J Biol Chem272: 7797-7800 (1997).
Zou, H. et al. “An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9.”J Biol Chem274:11549-11556 (1999).
Reed John C.
Tamm Ingo
DLA Piper (LLP) US
McGarry Sean R
The Burnham Institute
LandOfFree
Use of hepatitis B X-interacting protein (HBXIP) in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hepatitis B X-interacting protein (HBXIP) in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hepatitis B X-interacting protein (HBXIP) in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4160691